Talor M Tartaglia, | |
60 W Sunbridge Dr, Fayetteville, AR 72703-1822 | |
(479) 695-1240 | |
(479) 750-4843 |
Full Name | Talor M Tartaglia |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 60 W Sunbridge Dr, Fayetteville, Arkansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033769542 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | A1909128 (Arkansas) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Talor M Tartaglia, 2400 S 48th St, Springdale, AR 72762-6683 Ph: (479) 750-2020 | Talor M Tartaglia, 60 W Sunbridge Dr, Fayetteville, AR 72703-1822 Ph: (479) 695-1240 |
News Archive
Older adults are managing the stress of the coronavirus pandemic better than younger adults, reporting less depression and anxiety despite also experiencing greater general concern about COVID-19, according to a study recently published by researchers at the UConn School of Nursing.
Warfarin (an oral anticoagulant) therapy for patients with atrial fibrillation - the most common type of significant heart rhythm disorder - appears to be most beneficial for the oldest patients, for those who have had a prior stroke and for patients with multiple risk factors for stroke, according to a new study by Kaiser Permanente and Massachusetts General Hospital researchers.
Arrowhead Research Corporation today announced that its wholly owned subsidiary, Tego Biosciences, has completed a definitive asset purchase agreement for the sale of its non-cash intellectual property (IP) to Luna Innovations, Inc., a developer and manufacturer of new-generation products that include pharmaceutical nanomedicines
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.
› Verified 5 days ago